Abstract:10553 Background: Cancer-specific therapy requires the identification of the tumor origin. Detecting cancer and identifying the tumor origin in early stage can improve the survival and prognosis of cancer patients. However, early diagnosis of cancer is challenging as the early symptoms of cancer are mild or even absent. In order to improve the diagnostic efficacy and the patient compliance, we developed a two-stage model for cancer diagnosis and tissue of origin (TOO) classification, using DNA methylation profile evaluated through non-invasive blood-based testing as biomarker. Methods: cfDNA samples from 302 healthy and 598 cancer patients of 8 cancer types (colorectal, lung, liver, pancreatic, gastric, esophagus, breast and ovarian) were sequenced by our in-house-designed DNA methylation panel and randomly split into a training dataset (213:426) and a testing dataset (89:172). The testing dataset was reserved to evaluate the performance of models and would not be used during the feature selection and model development process. Methylation levels of cfDNA samples were measured by the methylated fragment ratios (MFRs) in methylated-correlated blocks (MCBs). We first selected pan-cancer markers by comparing the MFR values of MCBs between the healthy and the diseased individuals and developed a binary classifier (hyper-methylation score). Sample correctly predicted by the hyper-methylation score in the cancer group were then used for TOO marker selection and model fitting. TOO biomarkers were obtained by a series of pairwise comparisons of MFR values between any two cancer types. A deconvolution model was built to estimate the composition of ctDNA, which implied the tumor origin. Results: The hyper-methylation score model based on 135 MCB biomarkers achieved an area under the curve (AUC) of 0.89 in the training dataset and 0.85 in the testing dataset. Under a specificity of 94.8%, sensitivity was 66.2% in the training dataset. Using the 282 cases successfully being predicted, 583 TOO markers were selected to build the deconvolution model. In the testing dataset, the specificity was 95.5%, and the overall sensitivity was 66.3%. With increasing stage, sensitivity increased in all cancer types: 34.6%, 57.1%, 62.5% and 84.8% in stage I, II, III and IV respectively. In stage I-III, sensitivity was 52.3%. TOO classes were predicted in the 114 true positives from the hyper-methylation score model, producing a top 1 accuracy (true class matched the most probable class) of 75.4% and a top 2 accuracy (true class matched the first or the second most probable class) of 84.2%. Top 1 accuracy was 71.1% in stage I-III, vs. 84.0% in stage IV. Top 2 accuracy was 82.2% in stage I-III, vs. 90.0% in stage IV. Conclusions: Our cfDNA-based epigenetic method achieved outstanding performance either in pan-cancer detection or in TOO classification, and is a promising tool for early-stage cancer diagnosis.

A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling

A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primary

An ultrasensitive approach for cancer screening and tissue of origin prediction based on targeted methylation sequencing of cell-free DNA.

Multiplexed DNA Methylation Analysis in Colorectal Cancer Using Liquid Biopsy and Its Diagnostic and Predictive Value

DNA methylation profiling to determine the primary sites of metastatic cancers using formalin-fixed paraffin-embedded tissues

Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification

Accurate early-stage colorectal cancer detection through analysis of cell-free circulating tumor DNA (ctDNA) methylation patterns.

Abstract 3310: Non-invasive Diagnosis of Colorectal Cancer Via Targeted High-Throughput DNA Methylation Sequencing of Circulating Tumor DNA (Ctdna)

A Fragment-Based Algorithm for Identifying Pan-Cancer Differential Methylation Markers from Cfdna.

An Ultrasensitive Method for Noninvasive Pan-Cancer Early Detection Based on Targeted Methylation Sequencing of Cell-Free DNA.

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA

Diagnosis of pediatric central nervous system tumors using methylation profiling of cfDNA from cerebrospinal fluid

Highly Specific Multiplex DNA Methylation Detection for Liquid Biopsy of Colorectal Cancer

PR01.08 Simultaneous Multi-Cancer Detection and Tissue of Origin Prediction Via Targeted Bisulfite Sequencing of Plasma Cell-Free DNA

A novel artificial intelligence-enhanced electrochemical method for rapid methylation detection in cfDNA: Advancing multi-cancer early diagnosis.

Cell-Free DNA Methylation of Selected Genes Allows for Early Detection of the Major Cancers in Women

MetDecode: Methylation-based deconvolution of cell-free DNA for non-invasive multi-cancer typing

Early detection of the major male cancer types in blood-based liquid biopsies using a DNA methylation panel

DNA methylation profiling from circulating tumor DNA for early-detection of colorectal cancer.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

Non-invasive Diagnosis of Nature of Pulmonary Nodules Using the Whole Genome Methylation Sequencing of Circulating Cell-Free DNA.